【礼来(LLY.US)旗下候选抗癌药物Olomorasib获FDA授予孤儿药资格】智通财经APP获悉,美国食品药品管理局(FDA)已授予礼来(LLY.US)旗下候选药物Olomorasib用于治疗KRAS
G12C突变型非小细胞肺癌(NSCLC)的孤儿药资格。据悉,该药物目前正处于用于上述适应症的三期临床试验阶段。其正在接受评估,作为一线治疗方案,用于KRAS
G12C突变型晚期非小细胞肺癌患者,与Keytruda(帕博利珠单抗)联合使用,可选择是否同时联合化疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.